{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:37:35Z","timestamp":1790537855423,"version":"4.1.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1038\/nrneurol.2018.4","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:21:01Z","timestamp":1518135661000},"page":"214-224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":218,"title":["Advances in therapy for spinal muscular atrophy: promises and challenges"],"prefix":"10.1038","volume":"14","author":[{"given":"Ewout J. N.","family":"Groen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Gillingwater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,9]]},"reference":[{"key":"BFnrneurol20184_CR1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155\u2013165 (1995).","journal-title":"Cell"},{"key":"BFnrneurol20184_CR2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart, I. E. C. et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J. Rare Dis. 12, 124 (2017).","journal-title":"Orphanet J. Rare Dis."},{"key":"BFnrneurol20184_CR3","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn, M. R. & Wang, C. H. Spinal muscular atrophy. Lancet 371, 2120\u20132133 (2008).","journal-title":"Lancet"},{"key":"BFnrneurol20184_CR4","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","volume":"96","author":"CL Lorson","year":"1999","unstructured":"Lorson, C. L., Hahnen, E., Androphy, E. J. & Wirth, B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl Acad. Sci. USA 96, 6307\u20136311 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol20184_CR5","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","volume":"8","author":"UR Monani","year":"1999","unstructured":"Monani, U. R. et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol. Genet. 8, 1177\u20131183 (1999).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR6","doi-asserted-by":"crossref","first-page":"43741","DOI":"10.1074\/jbc.M112.372318","volume":"287","author":"KJ Han","year":"2012","unstructured":"Han, K. J. et al. Ubiquitin-specific protease 9x deubiquitinates and stabilizes the spinal muscular atrophy protein-survival motor neuron. J. Biol. Chem. 287, 43741\u201343752 (2012).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol20184_CR7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng0797-265","volume":"16","author":"S Lefebvre","year":"1997","unstructured":"Lefebvre, S. et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat. Genet. 16, 265\u2013269 (1997).","journal-title":"Nat. Genet."},{"key":"BFnrneurol20184_CR8","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1093\/hmg\/6.11.1961","volume":"6","author":"G Battaglia","year":"1997","unstructured":"Battaglia, G., Princivalle, A., Forti, F., Lizier, C. & Zeviani, M. Expression of the SMN gene, the spinal muscular atrophy determining gene, in the mammalian central nervous system. Hum. Mol. Genet. 6, 1961\u20131971 (1997).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR9","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/hmg\/7.12.1927","volume":"7","author":"P Burlet","year":"1998","unstructured":"Burlet, P. et al. The distribution of SMN protein complex in human fetal tissues and its alteration in spinal muscular atrophy. Hum. Mol. Genet. 7, 1927\u20131933 (1998).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR10","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/hmg\/6.8.1205","volume":"6","author":"DD Coovert","year":"1997","unstructured":"Coovert, D. D. et al. The survival motor neuron protein in spinal muscular atrophy. Hum. Mol. Genet. 6, 1205\u20131214 (1997).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR11","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.4155\/fmc.12.131","volume":"4","author":"MA Lorson","year":"2012","unstructured":"Lorson, M. A. & Lorson, C. L. SMN-inducing compounds for the treatment of spinal muscular atrophy. Future Med. Chem. 4, 2067\u20132084 (2012).","journal-title":"Future Med. Chem."},{"key":"BFnrneurol20184_CR12","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/gt.2017.34","volume":"24","author":"NN Singh","year":"2017","unstructured":"Singh, N. N., Howell, M. D., Androphy, E. J. & Singh, R. N. How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy. Gene Ther. 24, 520\u2013526 (2017).","journal-title":"Gene Ther."},{"key":"BFnrneurol20184_CR13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nature02919","volume":"431","author":"J Schmutz","year":"2004","unstructured":"Schmutz, J. et al. The DNA sequence and comparative analysis of human chromosome 5. Nature 431, 268\u2013274 (2004).","journal-title":"Nature"},{"key":"BFnrneurol20184_CR14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/hmg\/9.3.333","volume":"9","author":"UR Monani","year":"2000","unstructured":"Monani, U. R. et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(\u2212\/\u2212) mice and results in a mouse with spinal muscular atrophy. Hum. Mol. Genet. 9, 333\u2013339 (2000).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/jnnp-2016-314292","volume":"88","author":"RI Wadman","year":"2017","unstructured":"Wadman, R. I. et al. Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0\u20134. J. Neurol. Neurosurg. Psychiatry 88, 365\u2013367 (2017).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol20184_CR16","doi-asserted-by":"crossref","first-page":"e33572","DOI":"10.1371\/journal.pone.0033572","volume":"7","author":"TO Crawford","year":"2012","unstructured":"Crawford, T. O. et al. Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. PLoS ONE 7, e33572 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrneurol20184_CR17","doi-asserted-by":"crossref","first-page":"e0167087","DOI":"10.1371\/journal.pone.0167087","volume":"11","author":"RI Wadman","year":"2016","unstructured":"Wadman, R. I. et al. A comparative study of SMN protein and mRNA in blood and fibroblasts in patients with spinal muscular atrophy and healthy controls. PLoS ONE 11, e0167087 (2016).","journal-title":"PLoS ONE"},{"key":"BFnrneurol20184_CR18","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ajhg.2016.07.014","volume":"99","author":"S Hosseinibarkooie","year":"2016","unstructured":"Hosseinibarkooie, S. et al. The power of human protective modifiers: PLS3 and CORO1C unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype. Am. J. Hum. Genet. 99, 647\u2013665 (2016).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrneurol20184_CR19","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1126\/science.1155085","volume":"320","author":"GE Oprea","year":"2008","unstructured":"Oprea, G. E. et al. Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science 320, 524\u2013527 (2008).","journal-title":"Science"},{"key":"BFnrneurol20184_CR20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ajhg.2017.01.005","volume":"100","author":"M Riessland","year":"2017","unstructured":"Riessland, M. et al. Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis. Am. J. Hum. Genet. 100, 297\u2013315 (2017).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrneurol20184_CR21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbagrm.2016.12.008","volume":"1860","author":"RN Singh","year":"2017","unstructured":"Singh, R. N., Howell, M. D., Ottesen, E. W. & Singh, N. N. Diverse role of survival motor neuron protein. Biochim. Biophys. Acta 1860, 299\u2013315 (2017).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnrneurol20184_CR22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/joa.12419","volume":"228","author":"RA Powis","year":"2016","unstructured":"Powis, R. A. & Gillingwater, T. H. Selective loss of alpha motor neurons with sparing of gamma motor neurons and spinal cord cholinergic neurons in a mouse model of spinal muscular atrophy. J. Anat. 228, 443\u2013451 (2016).","journal-title":"J. Anat."},{"key":"BFnrneurol20184_CR23","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nn.4561","volume":"20","author":"EV Fletcher","year":"2017","unstructured":"Fletcher, E. V. et al. Reduced sensory synaptic excitation impairs motor neuron function via Kv2.1 in spinal muscular atrophy. Nat. Neurosci. 20, 905\u2013916 (2017).","journal-title":"Nat. Neurosci."},{"key":"BFnrneurol20184_CR24","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1093\/hmg\/ddt612","volume":"23","author":"G Hunter","year":"2014","unstructured":"Hunter, G., Aghamaleky Sarvestany, A., Roche, S. L., Symes, R. C. & Gillingwater, T. H. SMN-dependent intrinsic defects in Schwann cells in mouse models of spinal muscular atrophy. Hum. Mol. Genet. 23, 2235\u20132250 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.neuron.2010.12.032","volume":"69","author":"GZ Mentis","year":"2011","unstructured":"Mentis, G. Z. et al. Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy. Neuron 69, 453\u2013467 (2011).","journal-title":"Neuron"},{"key":"BFnrneurol20184_CR26","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1523\/JNEUROSCI.3534-15.2016","volume":"36","author":"C Zhou","year":"2016","unstructured":"Zhou, C., Feng, Z. & Ko, C. P. Defects in motoneuron-astrocyte interactions in spinal muscular atrophy. J. Neurosci. 36, 2543\u20132553 (2016).","journal-title":"J. Neurosci."},{"key":"BFnrneurol20184_CR27","doi-asserted-by":"crossref","first-page":"8691","DOI":"10.1523\/JNEUROSCI.0417-15.2015","volume":"35","author":"S Tisdale","year":"2015","unstructured":"Tisdale, S. & Pellizzoni, L. Disease mechanisms and therapeutic approaches in spinal muscular atrophy. J. Neurosci. 35, 8691\u20138700 (2015).","journal-title":"J. Neurosci."},{"key":"BFnrneurol20184_CR28","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0092-8674(00)80368-2","volume":"90","author":"U Fischer","year":"1997","unstructured":"Fischer, U., Liu, Q. & Dreyfuss, G. The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis. Cell 90, 1023\u20131029 (1997).","journal-title":"Cell"},{"key":"BFnrneurol20184_CR29","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0092-8674(00)80367-0","volume":"90","author":"Q Liu","year":"1997","unstructured":"Liu, Q., Fischer, U., Wang, F. & Dreyfuss, G. The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins. Cell 90, 1013\u20131021 (1997).","journal-title":"Cell"},{"key":"BFnrneurol20184_CR30","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1126\/science.1074962","volume":"298","author":"L Pellizzoni","year":"2002","unstructured":"Pellizzoni, L., Yong, J. & Dreyfuss, G. Essential role for the SMN complex in the specificity of snRNP assembly. Science 298, 1775\u20131779 (2002).","journal-title":"Science"},{"key":"BFnrneurol20184_CR31","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.celrep.2017.01.059","volume":"18","author":"PG Donlin-Asp","year":"2017","unstructured":"Donlin-Asp, P. G. et al. The survival of motor neuron protein acts as a molecular chaperone for mRNP assembly. Cell Rep. 18, 1660\u20131673 (2017).","journal-title":"Cell Rep."},{"key":"BFnrneurol20184_CR32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nsmb.3167","volume":"23","author":"BR So","year":"2016","unstructured":"So, B. R. et al. A U1 snRNP-specific assembly pathway reveals the SMN complex as a versatile hub for RNP exchange. Nat. Struct. Mol. Biol. 23, 225\u2013230 (2016).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"BFnrneurol20184_CR33","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0960-9822(01)00316-5","volume":"11","author":"L Pellizzoni","year":"2001","unstructured":"Pellizzoni, L., Baccon, J., Charroux, B. & Dreyfuss, G. The survival of motor neurons (SMN) protein interacts with the snoRNP proteins fibrillarin and GAR1. Curr. Biol. 11, 1079\u20131088 (2001).","journal-title":"Curr. Biol."},{"key":"BFnrneurol20184_CR34","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/nar\/gks1224","volume":"41","author":"N Piazzon","year":"2013","unstructured":"Piazzon, N. et al. Implication of the SMN complex in the biogenesis and steady state level of the signal recognition particle. Nucleic Acids Res. 41, 1255\u20131272 (2013).","journal-title":"Nucleic Acids Res."},{"key":"BFnrneurol20184_CR35","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1242\/bio.018804","volume":"5","author":"AR Poole","year":"2016","unstructured":"Poole, A. R. & Hebert, M. D. SMN and coilin negatively regulate dyskerin association with telomerase RNA. Biol. Open 5, 726\u2013735 (2016).","journal-title":"Biol. Open"},{"key":"BFnrneurol20184_CR36","doi-asserted-by":"crossref","first-page":"e1000773","DOI":"10.1371\/journal.pgen.1000773","volume":"5","author":"D Baumer","year":"2009","unstructured":"Baumer, D. et al. Alternative splicing events are a late feature of pathology in a mouse model of spinal muscular atrophy. PLoS Genet. 5, e1000773 (2009).","journal-title":"PLoS Genet."},{"key":"BFnrneurol20184_CR37","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.cell.2008.03.031","volume":"133","author":"Z Zhang","year":"2008","unstructured":"Zhang, Z. et al. SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell 133, 585\u2013600 (2008).","journal-title":"Cell"},{"key":"BFnrneurol20184_CR38","first-page":"133","volume-title":"Spinal Muscular Atrophy","author":"P Boyd","year":"2016","unstructured":"Boyd, P. & Gillingwater, T. H. in Spinal Muscular Atrophy (eds Sumner, C. J., Paushkin, S. & Ko, C. P.) 133\u2013151 (Elsevier, 2016)."},{"key":"BFnrneurol20184_CR39","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/hmg\/11.12.1439","volume":"11","author":"C Cifuentes-Diaz","year":"2002","unstructured":"Cifuentes-Diaz, C. et al. Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal muscular atrophy mouse model. Hum. Mol. Genet. 11, 1439\u20131447 (2002).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR40","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1093\/hmg\/ddn156","volume":"17","author":"S Kariya","year":"2008","unstructured":"Kariya, S. et al. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum. Mol. Genet. 17, 2552\u20132569 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR41","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/hmg\/ddm367","volume":"17","author":"LM Murray","year":"2008","unstructured":"Murray, L. M. et al. Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Hum. Mol. Genet. 17, 949\u2013962 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR42","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1523\/JNEUROSCI.4434-08.2009","volume":"29","author":"L Kong","year":"2009","unstructured":"Kong, L. et al. Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. J. Neurosci. 29, 842\u2013851 (2009).","journal-title":"J. Neurosci."},{"key":"BFnrneurol20184_CR43","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/hmg\/ddp506","volume":"19","author":"LM Murray","year":"2010","unstructured":"Murray, L. M. et al. Pre-symptomatic development of lower motor neuron connectivity in a mouse model of severe spinal muscular atrophy. Hum. Mol. Genet. 19, 420\u2013433 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/path.4080","volume":"229","author":"R Martinez-Hernandez","year":"2013","unstructured":"Martinez-Hernandez, R. et al. Synaptic defects in type I spinal muscular atrophy in human development. J. Pathol. 229, 49\u201361 (2013).","journal-title":"J. Pathol."},{"key":"BFnrneurol20184_CR45","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1212\/WNL.0b013e3182749eca","volume":"79","author":"RI Wadman","year":"2012","unstructured":"Wadman, R. I., Vrancken, A. F., van den Berg, L. H. & van der Pol, W. L. Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3. Neurology 79, 2050\u20132055 (2012).","journal-title":"Neurology"},{"key":"BFnrneurol20184_CR46","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1172\/JCI72017","volume":"124","author":"S Kariya","year":"2014","unstructured":"Kariya, S. et al. Requirement of enhanced survival motoneuron protein imposed during neuromuscular junction maturation. J. Clin. Invest. 124, 785\u2013800 (2014).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol20184_CR47","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/nan.12014","volume":"39","author":"TH Gillingwater","year":"2013","unstructured":"Gillingwater, T. H. & Wishart, T. M. Mechanisms underlying synaptic vulnerability and degeneration in neurodegenerative disease. Neuropathol. Appl. Neurobiol. 39, 320\u2013334 (2013).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"BFnrneurol20184_CR48","first-page":"506","volume":"9","author":"HR Fuller","year":"2015","unstructured":"Fuller, H. R. et al. Spinal muscular atrophy patient iPSC-derived motor neurons have reduced expression of proteins important in neuronal development. Front. Cell. Neurosci. 9, 506 (2015).","journal-title":"Front. Cell. Neurosci."},{"key":"BFnrneurol20184_CR49","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ajhg.2007.09.009","volume":"82","author":"J Ramser","year":"2008","unstructured":"Ramser, J. et al. Rare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophy. Am. J. Hum. Genet. 82, 188\u2013193 (2008).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrneurol20184_CR50","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1172\/JCI71318","volume":"124","author":"TM Wishart","year":"2014","unstructured":"Wishart, T. M. et al. Dysregulation of ubiquitin homeostasis and beta-catenin signaling promote spinal muscular atrophy. J. Clin. Invest. 124, 1821\u20131834 (2014).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol20184_CR51","doi-asserted-by":"crossref","first-page":"e87908","DOI":"10.1172\/jci.insight.87908","volume":"1","author":"RA Powis","year":"2016","unstructured":"Powis, R. A. et al. Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy. JCI Insight 1, e87908 (2016).","journal-title":"JCI Insight"},{"key":"BFnrneurol20184_CR52","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00401-002-0638-1","volume":"105","author":"A Berger","year":"2003","unstructured":"Berger, A. et al. Severe depletion of mitochondrial DNA in spinal muscular atrophy. Acta Neuropathol. 105, 245\u2013251 (2003).","journal-title":"Acta Neuropathol."},{"key":"BFnrneurol20184_CR53","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaneurol.2015.0178","volume":"72","author":"M Ripolone","year":"2015","unstructured":"Ripolone, M. et al. Impaired muscle mitochondrial biogenesis and myogenesis in spinal muscular atrophy. JAMA Neurol. 72, 666\u2013675 (2015).","journal-title":"JAMA Neurol."},{"key":"BFnrneurol20184_CR54","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1002\/jnr.22106","volume":"87","author":"G Acsadi","year":"2009","unstructured":"Acsadi, G. et al. Mitochondrial dysfunction in a neural cell model of spinal muscular atrophy. J. Neurosci. Res. 87, 2748\u20132756 (2009).","journal-title":"J. Neurosci. Res."},{"key":"BFnrneurol20184_CR55","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1093\/hmg\/ddw262","volume":"25","author":"N Miller","year":"2016","unstructured":"Miller, N., Shi, H., Zelikovich, A. S. & Ma, Y. C. Motor neuron mitochondrial dysfunction in spinal muscular atrophy. Hum. Mol. Genet. 25, 3395\u20133406 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR56","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1242\/dmm.021766","volume":"9","author":"CC Xu","year":"2016","unstructured":"Xu, C. C., Denton, K. R., Wang, Z. B., Zhang, X. & Li, X. J. Abnormal mitochondrial transport and morphology as early pathological changes in human models of spinal muscular atrophy. Dis. Model. Mech. 9, 39\u201349 (2016).","journal-title":"Dis. Model. Mech."},{"key":"BFnrneurol20184_CR57","doi-asserted-by":"crossref","first-page":"e1006744","DOI":"10.1371\/journal.pgen.1006744","volume":"13","author":"PJ Boyd","year":"2017","unstructured":"Boyd, P. J. et al. Bioenergetic status modulates motor neuron vulnerability and pathogenesis in a zebrafish model of spinal muscular atrophy. PLoS Genet. 13, e1006744 (2017).","journal-title":"PLoS Genet."},{"key":"BFnrneurol20184_CR58","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/14789450.2017.1345631","volume":"14","author":"S Hosseinibarkooie","year":"2017","unstructured":"Hosseinibarkooie, S., Schneider, S. & Wirth, B. Advances in understanding the role of disease-associated proteins in spinal muscular atrophy. Expert Rev. Proteom. 14, 581\u2013592 (2017).","journal-title":"Expert Rev. Proteom."},{"key":"BFnrneurol20184_CR59","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12031-007-0024-5","volume":"32","author":"M Bowerman","year":"2007","unstructured":"Bowerman, M., Shafey, D. & Kothary, R. Smn depletion alters profilin II expression and leads to upregulation of the RhoA\/ROCK pathway and defects in neuronal integrity. J. Mol. Neurosci. 32, 120\u2013131 (2007).","journal-title":"J. Mol. Neurosci."},{"key":"BFnrneurol20184_CR60","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1093\/hmg\/ddr425","volume":"20","author":"A Nolle","year":"2011","unstructured":"Nolle, A. et al. The spinal muscular atrophy disease protein SMN is linked to the Rho-kinase pathway via profilin. Hum. Mol. Genet. 20, 4865\u20134878 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR61","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/hmg\/ddq021","volume":"19","author":"M Bowerman","year":"2010","unstructured":"Bowerman, M., Beauvais, A., Anderson, C. L. & Kothary, R. Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. Hum. Mol. Genet. 19, 1468\u20131478 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR62","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1741-7015-10-24","volume":"10","author":"M Bowerman","year":"2012","unstructured":"Bowerman, M., Murray, L. M., Boyer, J. G., Anderson, C. L. & Kothary, R. Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy. BMC Med. 10, 24 (2012).","journal-title":"BMC Med."},{"key":"BFnrneurol20184_CR63","doi-asserted-by":"crossref","first-page":"e89970","DOI":"10.1172\/jci.insight.89970","volume":"2","author":"KA Kaifer","year":"2017","unstructured":"Kaifer, K. A. et al. Plastin-3 extends survival and reduces severity in mouse models of spinal muscular atrophy. JCI Insight 2, e89970 (2017).","journal-title":"JCI Insight"},{"key":"BFnrneurol20184_CR64","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.neuron.2013.10.036","volume":"80","author":"CE Holt","year":"2013","unstructured":"Holt, C. E. & Schuman, E. M. The central dogma decentralized: new perspectives on RNA function and local translation in neurons. Neuron 80, 648\u2013657 (2013).","journal-title":"Neuron"},{"key":"BFnrneurol20184_CR65","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.neuron.2017.09.057","volume":"96","author":"M Kapur","year":"2017","unstructured":"Kapur, M., Monaghan, C. E. & Ackerman, S. L. Regulation of mRNA translation in neurons \u2014 a matter of life and death. Neuron 96, 616\u2013637 (2017).","journal-title":"Neuron"},{"key":"BFnrneurol20184_CR66","doi-asserted-by":"crossref","first-page":"10337","DOI":"10.1073\/pnas.1104928108","volume":"108","author":"B Akten","year":"2011","unstructured":"Akten, B. et al. Interaction of survival of motor neuron (SMN) and HuD proteins with mRNA cpg15 rescues motor neuron axonal deficits. Proc. Natl Acad. Sci. USA 108, 10337\u201310342 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol20184_CR67","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1523\/JNEUROSCI.2396-15.2016","volume":"36","author":"C Fallini","year":"2016","unstructured":"Fallini, C., Donlin-Asp, P. G., Rouanet, J. P., Bassell, G. J. & Rossoll, W. Deficiency of the survival of motor neuron protein impairs mRNA localization and local translation in the growth cone of motor neurons. J. Neurosci. 36, 3811\u20133820 (2016).","journal-title":"J. Neurosci."},{"key":"BFnrneurol20184_CR68","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1523\/JNEUROSCI.3631-10.2011","volume":"31","author":"C Fallini","year":"2011","unstructured":"Fallini, C. et al. The survival of motor neuron (SMN) protein interacts with the mRNA-binding protein HuD and regulates localization of poly(A) mRNA in primary motor neuron axons. J. Neurosci. 31, 3914\u20133925 (2011).","journal-title":"J. Neurosci."},{"key":"BFnrneurol20184_CR69","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/hmg\/ddq500","volume":"20","author":"L Hubers","year":"2011","unstructured":"Hubers, L. et al. HuD interacts with survival motor neuron protein and can rescue spinal muscular atrophy-like neuronal defects. Hum. Mol. Genet. 20, 553\u2013579 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR70","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1083\/jcb.200304128","volume":"163","author":"W Rossoll","year":"2003","unstructured":"Rossoll, W. et al. Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons. J. Cell Biol. 163, 801\u2013812 (2003).","journal-title":"J. Cell Biol."},{"key":"BFnrneurol20184_CR71","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.1093\/hmg\/ddu350","volume":"23","author":"MJ Kye","year":"2014","unstructured":"Kye, M. J. et al. SMN regulates axonal local translation via miR-183\/mTOR pathway. Hum. Mol. Genet. 23, 6318\u20136331 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR72","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1093\/nar\/gkv1334","volume":"44","author":"G Sanchez","year":"2016","unstructured":"Sanchez, G. et al. A novel role for CARM1 in promoting nonsense-mediated mRNA decay: potential implications for spinal muscular atrophy. Nucleic Acids Res. 44, 2661\u20132676 (2016).","journal-title":"Nucleic Acids Res."},{"key":"BFnrneurol20184_CR73","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/hmg\/dds474","volume":"22","author":"G Sanchez","year":"2013","unstructured":"Sanchez, G. et al. A novel function for the survival motoneuron protein as a translational regulator. Hum. Mol. Genet. 22, 668\u2013684 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR74","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.celrep.2017.10.010","volume":"21","author":"P Bernabo","year":"2017","unstructured":"Bernabo, P. et al. In vivo translatome profiling in spinal muscular atrophy reveals a role for SMN protein in ribosome biology. Cell Rep. 21, 953\u2013965 (2017).","journal-title":"Cell Rep."},{"key":"BFnrneurol20184_CR75","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","volume":"478","author":"Y Hua","year":"2011","unstructured":"Hua, Y. et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478, 123\u2013126 (2011).","journal-title":"Nature"},{"key":"BFnrneurol20184_CR76","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1089\/hum.2012.211","volume":"24","author":"H Zhou","year":"2013","unstructured":"Zhou, H. et al. A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice. Hum. Gene Ther. 24, 331\u2013342 (2013).","journal-title":"Hum. Gene Ther."},{"key":"BFnrneurol20184_CR77","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga, C. A. et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology 86, 890\u2013897 (2016).","journal-title":"Neurology"},{"key":"BFnrneurol20184_CR78","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel, R. S. et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388, 3017\u20133026 (2016).","journal-title":"Lancet"},{"key":"BFnrneurol20184_CR79","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723\u20131732 (2017).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol20184_CR80","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.1605731113","volume":"113","author":"SM Hammond","year":"2016","unstructured":"Hammond, S. M. et al. Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc. Natl Acad. Sci. USA 113, 10962\u201310967 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol20184_CR81","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1126\/science.1250127","volume":"345","author":"NA Naryshkin","year":"2014","unstructured":"Naryshkin, N. A. et al. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 345, 688\u2013693 (2014).","journal-title":"Science"},{"key":"BFnrneurol20184_CR82","doi-asserted-by":"crossref","first-page":"e88427","DOI":"10.1172\/jci.insight.88427","volume":"1","author":"MB Abera","year":"2016","unstructured":"Abera, M. B. et al. ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice. JCI Insight 1, e88427 (2016).","journal-title":"JCI Insight"},{"key":"BFnrneurol20184_CR83","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1172\/JCI29562","volume":"117","author":"AM Avila","year":"2007","unstructured":"Avila, A. M. et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J. Clin. Invest. 117, 659\u2013671 (2007).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol20184_CR84","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1172\/JCI46276","volume":"121","author":"F Farooq","year":"2011","unstructured":"Farooq, F. et al. Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway. J. Clin. Invest. 121, 3042\u20133050 (2011).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol20184_CR85","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1091\/mbc.e13-01-0042","volume":"24","author":"DY Kwon","year":"2013","unstructured":"Kwon, D. Y. et al. The E3 ubiquitin ligase mind bomb 1 ubiquitinates and promotes the degradation of survival of motor neuron protein. Mol. Biol. Cell 24, 1863\u20131871 (2013).","journal-title":"Mol. Biol. Cell"},{"key":"BFnrneurol20184_CR86","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/hmg\/ddq023","volume":"19","author":"M Riessland","year":"2010","unstructured":"Riessland, M. et al. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum. Mol. Genet. 19, 1492\u20131506 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR87","doi-asserted-by":"crossref","first-page":"e21296","DOI":"10.1371\/journal.pone.0021296","volume":"6","author":"JT Kissel","year":"2011","unstructured":"Kissel, J. T. et al. SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PLoS ONE 6, e21296 (2011).","journal-title":"PLoS ONE"},{"key":"BFnrneurol20184_CR88","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/JND-150081","volume":"2","author":"SR Renusch","year":"2015","unstructured":"Renusch, S. R. et al. Spinal muscular atrophy biomarker measurements from blood samples in a clinical trial of valproic acid in ambulatory adults. J. Neuromuscul. Dis. 2, 119\u2013130 (2015).","journal-title":"J. Neuromuscul. Dis."},{"issue":"2","key":"BFnrneurol20184_CR89","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/mus.25776","volume":"57","author":"Kristin J. Krosschell","year":"2017","unstructured":"Krosschell, K. J. et al. Clinical trial of L-carnitine and valproic acid in spinal muscular atrophy type I. Muscle Nerve https:\/\/doi.org\/10.1002\/mus.25776 (2017).","journal-title":"Muscle & Nerve"},{"key":"BFnrneurol20184_CR90","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/hmg\/ddq514","volume":"20","author":"E Dominguez","year":"2011","unstructured":"Dominguez, E. et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum. Mol. Genet. 20, 681\u2013693 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR91","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","volume":"28","author":"KD Foust","year":"2010","unstructured":"Foust, K. D. et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol. 28, 271\u2013274 (2010).","journal-title":"Nat. Biotechnol."},{"key":"BFnrneurol20184_CR92","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1172\/JCI41615","volume":"120","author":"MA Passini","year":"2010","unstructured":"Passini, M. A. et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J. Clin. Invest. 120, 1253\u20131264 (2010).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol20184_CR93","doi-asserted-by":"crossref","first-page":"35ra42","DOI":"10.1126\/scitranslmed.3000830","volume":"2","author":"CF Valori","year":"2010","unstructured":"Valori, C. F. et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci. Transl Med. 2, 35ra42 (2010).","journal-title":"Sci. Transl Med."},{"key":"BFnrneurol20184_CR94","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713\u20131722 (2017).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol20184_CR95","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(17)30085-6","volume":"16","author":"E Bertini","year":"2017","unstructured":"Bertini, E. et al. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 16, 513\u2013522 (2017).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol20184_CR96","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/jpet.114.222224","volume":"353","author":"DT Hwee","year":"2015","unstructured":"Hwee, D. T. et al. The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure. J. Pharmacol. Exp. Ther. 353, 159\u2013168 (2015).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrneurol20184_CR97","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/gt.2017.47","volume":"24","author":"V Christie-Brown","year":"2017","unstructured":"Christie-Brown, V., Mitchell, J. & Talbot, K. The SMA Trust: the role of a disease-focused research charity in developing treatments for SMA. Gene Ther. 24, 544\u2013546 (2017).","journal-title":"Gene Ther."},{"key":"BFnrneurol20184_CR98","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1016\/S0140-6736(16)32390-X","volume":"388","author":"TH Gillingwater","year":"2016","unstructured":"Gillingwater, T. H. Dawn of a new therapeutic era for spinal muscular atrophy. Lancet 388, 2964\u20132965 (2016).","journal-title":"Lancet"},{"key":"BFnrneurol20184_CR99","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2017.0665","volume":"27","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus, A. FDA approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides. Nucleic Acid. Ther. 27, 67\u201369 (2017).","journal-title":"Nucleic Acid. Ther."},{"key":"BFnrneurol20184_CR100","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMe1712106","volume":"377","author":"AT van der Ploeg","year":"2017","unstructured":"van der Ploeg, A. T. The dilemma of two innovative therapies for spinal muscular atrophy. N. Engl. J. Med. 377, 1786\u20131787 (2017).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol20184_CR101","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0883073815627882","volume":"31","author":"M Hache","year":"2016","unstructured":"Hache, M. et al. Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience. J. Child Neurol. 31, 899\u2013906 (2016).","journal-title":"J. Child Neurol."},{"key":"BFnrneurol20184_CR102","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ana.24864","volume":"81","author":"MA Farrar","year":"2017","unstructured":"Farrar, M. A. et al. Emerging therapies and challenges in spinal muscular atrophy. Ann. Neurol. 81, 355\u2013368 (2017).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol20184_CR103","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1373\/clinchem.2012.183038","volume":"58","author":"SF Dobrowolski","year":"2012","unstructured":"Dobrowolski, S. F. et al. Newborn screening for spinal muscular atrophy by calibrated short-amplicon melt profiling. Clin. Chem. 58, 1033\u20131039 (2012).","journal-title":"Clin. Chem."},{"key":"BFnrneurol20184_CR104","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1373\/clinchem.2014.231019","volume":"61","author":"JL Taylor","year":"2015","unstructured":"Taylor, J. L. et al. Newborn blood spot screening test using multiplexed real-time PCR to simultaneously screen for spinal muscular atrophy and severe combined immunodeficiency. Clin. Chem. 61, 412\u2013419 (2015).","journal-title":"Clin. Chem."},{"key":"BFnrneurol20184_CR105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pediatrneurol.2016.09.008","volume":"66","author":"PJ Lin","year":"2017","unstructured":"Lin, P. J., Yeh, W. S. & Neumann, P. J. Willingness to pay for a newborn screening test for spinal muscular atrophy. Pediatr. Neurol. 66, 69\u201375 (2017).","journal-title":"Pediatr. Neurol."},{"key":"BFnrneurol20184_CR106","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1093\/hmg\/ddq300","volume":"19","author":"AK Bevan","year":"2010","unstructured":"Bevan, A. K. et al. Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum. Mol. Genet. 19, 3895\u20133905 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR107","first-page":"801","volume":"26","author":"MO Deguise","year":"2017","unstructured":"Deguise, M. O. et al. Immune dysregulation may contribute to disease pathogenesis in spinal muscular atrophy mice. Hum. Mol. Genet. 26, 801\u2013819 (2017).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR108","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/ana.24549","volume":"79","author":"E Somers","year":"2016","unstructured":"Somers, E. et al. Vascular defects and spinal cord hypoxia in spinal muscular atrophy. Ann. Neurol. 79, 217\u2013230 (2016).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol20184_CR109","doi-asserted-by":"crossref","first-page":"34635","DOI":"10.1038\/srep34635","volume":"6","author":"E Szunyogova","year":"2016","unstructured":"Szunyogova, E. et al. Survival Motor Neuron (SMN) protein is required for normal mouse liver development. Sci. Rep. 6, 34635 (2016).","journal-title":"Sci. Rep."},{"key":"BFnrneurol20184_CR110","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/joa.12546","volume":"230","author":"AK Thomson","year":"2017","unstructured":"Thomson, A. K. et al. Survival of motor neurone protein is required for normal postnatal development of the spleen. J. Anat. 230, 337\u2013346 (2017).","journal-title":"J. Anat."},{"key":"BFnrneurol20184_CR111","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13023-017-0613-5","volume":"12","author":"CA Wijngaarde","year":"2017","unstructured":"Wijngaarde, C. A. et al. Cardiac pathology in spinal muscular atrophy: a systematic review. Orphanet J. Rare Dis. 12, 67 (2017).","journal-title":"Orphanet J. Rare Dis."},{"key":"BFnrneurol20184_CR112","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.molmed.2012.11.002","volume":"19","author":"G Hamilton","year":"2013","unstructured":"Hamilton, G. & Gillingwater, T. H. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol. Med. 19, 40\u201350 (2013).","journal-title":"Trends Mol. Med."},{"key":"BFnrneurol20184_CR113","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12883-017-0853-y","volume":"17","author":"S McGraw","year":"2017","unstructured":"McGraw, S. et al. A qualitative study of perceptions of meaningful change in spinal muscular atrophy. BMC Neurol. 17, 68 (2017).","journal-title":"BMC Neurol."},{"key":"BFnrneurol20184_CR114","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/gt.2017.32","volume":"24","author":"NMP King","year":"2017","unstructured":"King, N. M. P. & Bishop, C. E. New treatments for serious conditions: ethical implications. Gene Ther. 24, 534\u2013538 (2017).","journal-title":"Gene Ther."},{"key":"BFnrneurol20184_CR115","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/gt.2017.48","volume":"24","author":"T Friedmann","year":"2017","unstructured":"Friedmann, T. Gene therapy for spinomuscular atrophy: a biomedical advance, a missed opportunity for more equitable drug pricing. Gene Ther. 24, 503\u2013505 (2017).","journal-title":"Gene Ther."},{"key":"BFnrneurol20184_CR116","doi-asserted-by":"crossref","first-page":"1297886","DOI":"10.1080\/20016689.2017.1297886","volume":"5","author":"KE Young","year":"2017","unstructured":"Young, K. E., Soussi, I., Hemels, M. & Toumi, M. A comparative study of orphan drug prices in Europe. J. Mark. Access Health Policy 5, 1297886 (2017).","journal-title":"J. Mark. Access Health Policy"},{"key":"BFnrneurol20184_CR117","doi-asserted-by":"crossref","first-page":"e0140002","DOI":"10.1371\/journal.pone.0140002","volume":"10","author":"T Gammie","year":"2015","unstructured":"Gammie, T., Lu, C. Y. & Babar, Z. U. Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. PLoS ONE 10, e0140002 (2015).","journal-title":"PLoS ONE"},{"key":"BFnrneurol20184_CR118","first-page":"1010","volume":"22","author":"R Penington","year":"2016","unstructured":"Penington, R. & Stubbings, J. A. Evaluation of specialty drug price trends using data from retrospective pharmacy sales transactions. J. Manag. Care Spec. Pharm. 22, 1010\u20131017 (2016).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"BFnrneurol20184_CR119","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12883-015-0473-3","volume":"15","author":"Y Qian","year":"2015","unstructured":"Qian, Y. et al. Understanding the experiences and needs of individuals with Spinal Muscular Atrophy and their parents: a qualitative study. BMC Neurol. 15, 217 (2015).","journal-title":"BMC Neurol."},{"key":"BFnrneurol20184_CR120","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1080\/13696998.2016.1198355","volume":"19","author":"EP Armstrong","year":"2016","unstructured":"Armstrong, E. P. et al. The economic burden of spinal muscular atrophy. J. Med. Econ. 19, 822\u2013826 (2016).","journal-title":"J. Med. Econ."},{"key":"BFnrneurol20184_CR121","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/13696998.2016.1202833","volume":"19","author":"TH Gillingwater","year":"2016","unstructured":"Gillingwater, T. H. Counting the cost of spinal muscular atrophy. J. Med. Econ. 19, 827\u2013828 (2016).","journal-title":"J. Med. Econ."},{"key":"BFnrneurol20184_CR122","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-016-0424-0","volume":"11","author":"C Klug","year":"2016","unstructured":"Klug, C. et al. Disease burden of spinal muscular atrophy in Germany. Orphanet J. Rare Dis. 11, 58 (2016).","journal-title":"Orphanet J. Rare Dis."},{"key":"BFnrneurol20184_CR123","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/mus.24670","volume":"52","author":"J Montes","year":"2015","unstructured":"Montes, J. et al. Spinal muscular atrophy functional composite score: A functional measure in spinal muscular atrophy. Muscle Nerve 52, 942\u2013947 (2015).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol20184_CR124","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","volume":"17","author":"MC Pera","year":"2017","unstructured":"Pera, M. C. et al. Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy. BMC Neurol. 17, 39 (2017).","journal-title":"BMC Neurol."},{"key":"BFnrneurol20184_CR125","doi-asserted-by":"crossref","first-page":"e0172346","DOI":"10.1371\/journal.pone.0172346","volume":"12","author":"D Ramsey","year":"2017","unstructured":"Ramsey, D. et al. Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool. PLoS One 12, e0172346 (2017).","journal-title":"PLoS One"},{"key":"BFnrneurol20184_CR126","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.nmd.2017.05.011","volume":"27","author":"EF Tizzano","year":"2017","unstructured":"Tizzano, E. F. & Finkel, R. S. Spinal muscular atrophy: a changing phenotype beyond the clinical trials. Neuromuscul. Disord. 27, 883\u2013889 (2017).","journal-title":"Neuromuscul. Disord."},{"key":"BFnrneurol20184_CR127","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.molmed.2015.08.003","volume":"21","author":"EJ Groen","year":"2015","unstructured":"Groen, E. J. & Gillingwater, T. H. UBA1: at the crossroads of ubiquitin homeostasis and neurodegeneration. Trends Mol. Med. 21, 622\u2013632 (2015).","journal-title":"Trends Mol. Med."},{"key":"BFnrneurol20184_CR128","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1093\/hmg\/ddt222","volume":"22","author":"EJ Groen","year":"2013","unstructured":"Groen, E. J. et al. ALS-associated mutations in FUS disrupt the axonal distribution and function of SMN. Hum. Mol. Genet. 22, 3690\u20133704 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR129","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1093\/hmg\/ddw247","volume":"25","author":"ND Perera","year":"2016","unstructured":"Perera, N. D. et al. Enhancing survival motor neuron expression extends lifespan and attenuates neurodegeneration in mutant TDP-43 mice. Hum. Mol. Genet. 25, 4080\u20134093 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol20184_CR130","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.celrep.2017.01.035","volume":"18","author":"N Rodriguez-Muela","year":"2017","unstructured":"Rodriguez-Muela, N. et al. Single-cell analysis of SMN reveals its broader role in neuromuscular disease. Cell Rep. 18, 1484\u20131498 (2017).","journal-title":"Cell Rep."},{"key":"BFnrneurol20184_CR131","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1038\/ncomms7171","volume":"6","author":"S Sun","year":"2015","unstructured":"Sun, S. et al. ALS-causative mutations in FUS\/TLS confer gain and loss of function by altered association with SMN and U1-snRNP. Nat. Commun. 6, 6171 (2015).","journal-title":"Nat. Commun."},{"key":"BFnrneurol20184_CR132","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.celrep.2012.08.025","volume":"2","author":"T Yamazaki","year":"2012","unstructured":"Yamazaki, T. et al. FUS-SMN protein interactions link the motor neuron diseases ALS and SMA. Cell Rep. 2, 799\u2013806 (2012).","journal-title":"Cell Rep."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2018.4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2018.4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrneurol.2018.4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2018.4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:23:02Z","timestamp":1684455782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2018.4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,9]]},"references-count":132,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["BFnrneurol20184"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2018.4","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,9]]},"assertion":[{"value":"9 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.H.G. and K.T. serve as Chair of the Scientific and Clinical Advisory Board and Trustee of the SMA Trust, respectively.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}